Glycemically-defined new-onset diabetes (gNOD) with onset ≤ 180 days preceding enrollment
Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score ≥ 3, based on validated risk stratification models
Provide written or remote informed consent
You may not be if
Prior diagnosis of pancreatic ductal adenocarcinoma (PDA)
Known hereditary cancer syndromes (e.g., BRCA1/2, Lynch syndrome, Peutz-Jeghers)
Prior history of pancreatic surgery
Pancreatic cyst surveillance at time of registration
Contraindications to contrast-enhanced CT imaging per standard clinical practice at time of registration
Clareo Health | A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer
